Affinia Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Affinia Therapeutics's estimated annual revenue is currently $12.9M per year.
- Affinia Therapeutics's estimated revenue per employee is $155,000
- Affinia Therapeutics's total funding is $170M.
Employee Data
- Affinia Therapeutics has 83 Employees.
- Affinia Therapeutics grew their employee count by 2% last year.
Affinia Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | SVP Tech Ops and CTO | Reveal Email/Phone |
2 | VP, Translational Sciences at Affinia Therapeutics | Reveal Email/Phone |
3 | VP Program and Alliance Management | Reveal Email/Phone |
4 | VP, Preclinical and Immunology | Reveal Email/Phone |
5 | VP Finance, Controller | Reveal Email/Phone |
6 | Controller, Director | Reveal Email/Phone |
7 | VP Business Development | Reveal Email/Phone |
8 | Chief Scientific Officer | Reveal Email/Phone |
9 | Director - In Vivo Studies | Reveal Email/Phone |
10 | Senior Director, Human Resources | Reveal Email/Phone |
Affinia Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Affinia Therapeutics?
We are working to methodically engineer durable gene therapies for people with devastating diseases.
keywords:N/A
$170M
Total Funding
83
Number of Employees
$12.9M
Revenue (est)
2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Affinia Therapeutics News
Cobb, who is the Chief Business Officer at Affinia Therapeutics, described their time at Harvard Business School as a straight cocktail...
Affinia Therapeutics' proprietary Affinia Rationally-designed Therapeutics (ART) platform consists of three pillars intended to synergistically...
Indications include metachromatic leukodystrophy, a rare, progressive, and fatal disease affecting the nervous system, and brain metastases secondary to HER2+ breast cancer, a common and deadly form of cancer – Affinia Therapeutics to use its proprietary technologies and capsids with improved pr ...
Affinia Therapeutics has raised a $110 million Series B co-led by EcoR1 Capital and Farallon Capital Management. Founded in 2019 and based in the Boston area, the company is developing gene therapies for diseases affecting the central nervous system and muscles. It was valued at $110 million in ...
Affinia Therapeutics, a Waltham-based biotech working on gene therapies to treat diseases using technology developed at Massachusetts Eye and Ear, said Monday it has raised $110 million in a new venture capital round. The company, which was founded in 2019 based on work pioneered by Luk Vandenb ...
Other Companies in Waltham
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $12.9M | 83 | 32% | $7.7M |
#2 | $13.3M | 83 | 2% | N/A |
#3 | $12.2M | 84 | -3% | $29.9M |
#4 | $14.9M | 85 | -1% | N/A |
#5 | $17.3M | 86 | -14% | $457M |